Sanofi Raises Profit Forecast on Blockbuster Dupixent Sales
Sanofi raised its forecasts for sales and profit this year for a second straight quarter on rising demand for its top-selling skin and asthma drug Dupixent.
By Ashleigh Furlong ยท Bloomberg
Sanofi raised its forecasts for sales and profit this year for a second straight quarter on rising demand for its top-selling skin and asthma drug Dupixent.